Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something...
top of page
Subscriber login:
SUBMIT
Remember me
Search
- 5 days ago
Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg
Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...
- Jul 14
IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals
Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.
- Jun 30
Jeffrey Casberg of IPD Analytics Gives Insight on Specialty Drugs in the Pipeline
In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline.
- May 30
Key Pharmaceutical Pipeline Developments: Insights from Industry Experts
Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from IPD presenters.
- May 15
Additional Price Cuts to Insulin are on the Way
Several drug manufacturers have announced price cuts on commonly prescribed insulin products. By Brock Bizzell and David Baker | Original...
- May 12
Jeffrey Casberg Predicts Generic, Biosimilar Competition in the Pharmaceutical Market
Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs...
- Apr 22
AMCP 2024: Key Takeaways From Leading Speakers
IPD Analytics speaks about key takeaways from the AJMC 2024 Annual Conference
- Apr 18
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
IPD presents at the AMCP 2024 annual meeting discussing the current promise and future potential of gene and cell therapies.
- Apr 18
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
IPD Analytics LLC. discusses the up to 50 generics that could be approved this year, including Victoza to treat patients with diabetes.
- Apr 12
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
Jeffrey Casberg of IPD Analytics LLC, talks about how payers are thinking about weight-loss drugs.
- Mar 22
Why Every Hospital Needs a Chief Pharmacy Officer in the C-Suite
A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins
- Dec 27, 2023
2024 Prediction from Jeffrey Casberg, M.S., RPh
Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory...
- Nov 6, 2023
Amgen Confirms US Aflibercept Filing As Regeneron Awaits Biocon Trial Fate
Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster.
- Oct 13, 2023
Specialty Generic Market to Exceed $40 Billion by 2027
The U.S. market for specialty generic drugs hit $23 billion in 2021, and is expected to reach nearly $43 billion by 2027, driven by the...
- Sep 21, 2023
Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More
A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to...
- Aug 29, 2023
CMS Releases List of Drugs for Medicare Price Negotiation
The Centers for Medicare and Medicaid Services (CMS) has released the list of the first 10 drugs to be negotiated under the Inflation...
- Aug 1, 2023
Using Technology to Transform Specialty Medication Access and Affordability
We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior...
- Jun 15, 2023
What to Look For in the Pipeline, Misconceptions of Drug Approvals and More with Jeffrey Casberg
Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the...
- Mar 28, 2023
PDTs, Biosimilars, Hot Topics at AMCP meeting | AMCP 2023
The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for...
- Mar 25, 2023
Jeffrey Casberg on Breakthrough Ophthalmic Drugs that Payers, Pharmacists Should Pay Attention To
Jeffrey Casberg, Senior Director of Pharmacy at IPD Analytics discusses some of the high-impact specialty drugs in various therapeutic...
- Mar 24, 2023
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne...
- Mar 24, 2023
Beta Thalassemia Requires Specialized Management for Patients, Payors and Pharmacists
Dr. Billings, PharmD, BCGP, and Dr. Mahler, PhD, of IPD Analytics discuss specialized treatment with Beta Thalassemia at AMCP 2023. By...
- Feb 14, 2023
Exclusive: Profiling Manufacturers’ Limited and Exclusive Pharmacy Networks for Specialty Drugs
A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...
bottom of page